GLMD — Galmed Pharmaceuticals Balance Sheet
0.000.00%
- $1.75m
- -$9.06m
- 29
- 58
- 23
- 29
Annual balance sheet for Galmed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 75.5 | 50.9 | 34.8 | 13.8 | 12.6 |
Net Total Receivables | 0.226 | 0.066 | 0.079 | 0.124 | 0.165 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 76.4 | 51.8 | 36.1 | 14.7 | 13.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.709 | 0.57 | 0.551 | 0.337 | 0.125 |
Long Term Investments | |||||
Total Assets | 77.1 | 52.4 | 36.6 | 16.6 | 16.6 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.93 | 8.01 | 5.88 | 3.09 | 2.75 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.29 | 8.23 | 6.11 | 3.14 | 2.75 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 69.9 | 44.2 | 30.5 | 13.4 | 13.9 |
Total Liabilities & Shareholders' Equity | 77.1 | 52.4 | 36.6 | 16.6 | 16.6 |
Total Common Shares Outstanding |